Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Phase 2 trial data shows up to 24.2% body weight reduction at the 12mg dose over 48 weeks
Cagrilintide (Long-Acting Amylin Analog) Amino acid sequence modified from native human amylin [3] Fatty acid acylation extends half-life to approximately 7 days [2] Selective amylin receptor agonist (AMY1, AMY2, AMY3) [4] Delays gastric emptying and reduces food intake [5] Controls postprandial glucose metabolism [6] Synergistic effects with GLP-1 receptor agonists [7] CagriSema: The Synergistic Combination One of the most significant developments in cagrilintide research is its combination with semaglutide (a GLP-1 receptor agonist), known as CagriSema
Methods Study Design and Data Source This retrospective cohort study identified adults with evidence of T2DM and a recorded prescription of dulaglutide or semaglutide using the IQVIA Longitudinal Prescription Data (LRx) for France and Italy between February 1, 2020 and December 31, 2022
It's also approved for obstructive sleep apnea
US$ 28.20
US$ 21.45
US$ 28.95
US$ 22.80
